A Phase 1B, Randomized, Placebo-Controlled, Double-Blind, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Q203 When Administered Orally to Healthy Adult Subjects
Phase of Trial: Phase I
Latest Information Update: 13 Oct 2017
At a glance
- Drugs Q 203 (Primary)
- Indications Tuberculosis
- Focus Adverse reactions
- Sponsors Qurient Co
- 09 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2017.
- 01 Sep 2016 Status changed from not yet recruiting to recruiting.
- 09 Aug 2016 New trial record